You are here: Home » News-IANS » Health-Medicine
Business Standard

Oral drugs may protect cancer patients from blood clots

IANS  |  London 

Taking oral drugs daily can be an effective treatment for nearly 10 million patients worldwide suffering from a deadly condition, results from a have showed.

People with have an increased risk of developing blood clots, with roughly one in five experiencing (VTE) -- either a in a deep vein or a condition in which one or more arteries in the lungs become blocked by a

The results from the called "select-d" suggested that prescribing the oral drug rivaroxaban significantly reduced VTE recurrence among patients with

"Clinicians were already adopting the oral drug into practice for non-cancer patients and now they have data from this study to indicate that this form of treatment is an alternative option for many cancer patients who have a clot," said Annie Young, at in the Britain.

Although there are many causes and risk factors for VTE, cancer patients are particularly at risk due to a combination of factors such as immobility, as well as chemotherapy, the said.

For the "select-d" trial, researchers enrolled 406 patients who had cancer and VTE; most (69 per cent) were receiving (typically chemotherapy) at the time of their VTE.

Half were randomly assigned to receive low-molecular-weight heparin (dalteparin) and half were given the oral drug rivaroxaban. After six months of treatment, the VTE recurrence rate was four per cent among those taking the tablet and 11 per cent in those receiving dalteparin.

The results for secondary outcomes were mixed, the said.

In patients receiving rivaroxaban, there were around the same percentage of major bleeding events (6 per cent) as those receiving dalteparin (4 per cent) but a marked and significant increase in clinically relevant non-major bleeds (13 per cent) with rivaroxaban compared to those having low molecular weight heparin (4 per cent).

The reason for increased bleeding is not known. It may be because rivaroxaban is more 'potent', the paper published in said.



(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Sun, May 13 2018. 13:02 IST